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Abstract
Variations in the POLG1 gene encoding the catalytic subunit of the mitochondrial DNA polymerase gamma, have
recently been associated with Parkinson’s disease (PD), especially in patients diagnosed with progressive external
ophthalmoplegia (PEO). However, the majority of the studies reporting this association mainly focused on the
genetic identification of the variation in POLG1 in PD patient primary cells, and determination of mitochondrial DNA
copy number, providing little information about the cellular alterations existing in patient brain cells, in particular
dopaminergic neurons. Therefore, through the use of induced pluripotent stem cells (iPSCs), we assessed cellular
alterations in novel p.Q811R POLG1 (POLG1Q811R) variant midbrain dopaminergic neuron-containing spheroids
(MDNS) from a female patient who developed early-onset PD, and compared them to cultures derived from a
healthy control of the same gender. Both POLG1 variant and control MDNS contained functional midbrain
regionalized TH/FOXA2-positive dopaminergic neurons, capable of releasing dopamine. Western blot analysis
identified the presence of high molecular weight oligomeric alpha-synuclein in POLG1Q811R MDNS compared to
control cultures. In order to assess POLG1Q811R-related cellular alterations within the MDNS, we applied mass-
spectrometry based quantitative proteomic analysis. In total, 6749 proteins were identified, with 61 significantly
differentially expressed between POLG1Q811R and control samples. Pro- and anti-inflammatory signaling and
pathways involved in energy metabolism were altered. Notably, increased glycolysis in POLG1Q811R MDNS was
suggested by the increase in PFKM and LDHA levels and confirmed using functional analysis of glycolytic rate and
oxygen consumption levels. Our results validate the use of iPSCs to assess cellular alterations in relation to PD
pathogenesis, in a unique PD patient carrying a novel p.Q811R variation in POLG1, and identify several altered
pathways that may be relevant to PD pathogenesis.
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Introduction
Parkinson’s Disease (PD) is the most prevalent neuro-
degenerative movement disorder associated with pro-
gressive dopaminergic neuronal loss in the substantia
nigra pars compacta (SNpc). Despite extensive re-
search efforts, the underlying cause of PD largely re-
mains unknown [18]. However, a number of cellular
processes, including mitochondrial function, have
been implicated in the aetiology of PD [21, 25, 36].
First insights into the role of mitochondria in PD
came from the observation that 1-methyl-4-phenyl-1,
2,3,6-tetrahydropyridine (MPTP) induces dopamine
neuron death through inhibition of the complex I of
the mitochondrial respiratory chain, resulting in par-
kinsonism [51]. Later, a number of genes associated
with familial forms of PD were identified to play a
role in the maintenance of mitochondrial function,
further suggesting its involvement in PD pathogenesis
[1, 52]. Moreover, mitochondrial DNA (mtDNA) vari-
ations and depletion in PD have been extensively in-
vestigated, although without definitive conclusions
[48]. Notably, higher levels of mtDNA deletions in
SNpc of both PD and aged brains have been reported
[9, 40], and reduced mtDNA copy number has been
suggested as a biomarker of PD [19, 54].
The mitochondrial DNA polymerase gamma encoded by
the nuclear POLG1 gene, is responsible for the synthesis of
mtDNA [26]. Association of variants of POLG1 with parkin-
sonism was first reported in 2004, a study of seven families
with POLG1-related progressive external ophthalmoplegia
(PEO) revealed a co-segregation of parkinsonism with
POLG1 variations, with the age of onset of parkinsonism
varying between 36 and 75 years; post-mortem examination
of two patients showed loss of pigmented dopaminergic
neurons in the SNpc, but no presence of Lewy Body path-
ology [44]. In the same year, another study described a fam-
ily with PEO, neuropathy and late-onset parkinsonism [45].
POLG1-related PEO can occur in either autosomal recessive
(arPEO) form, characterized by ptosis and ophthalmopar-
esis, or autosomal dominant (adPEO) form that can include
symptoms of myopathy, hearing loss, cataracts, ovarian fail-
ure, axonal neuropathy, ataxia, depression and parkinsonism
[55]. Since then, additional cases of POLG1-associated par-
kinsonism have been described, often secondary to PEO and
ataxia, with late age-of-onset, complete or partial L- DOPA
response, and Lewy body pathology, but only in some cases
[10, 56, 63]. However, early-onset POLG1 variant-related
parkinsonism has also been observed in patients without
PEO [17, 47]. Interestingly, a study of eleven patients with
POLG1 variant-related encephalopathy revealed severe ni-
gral neuronal loss and nigrostriatal depletion through DAT
imaging, without any clinical signs of parkinsonism [74].
Here, we present a case study of a female patient
with a novel variation in POLG1 (p.Q811R), who was
diagnosed with early-onset parkinsonism, and subse-
quently, adPEO. We employed a recently developed
protocol to differentiate patient-derived induced pluri-
potent stem cells (iPSCs) into 3D midbrain dopamin-
ergic neuron-containing spheroids (MDNS) [35] to
examine POLG1Q811R cellular alterations.
Results
Case description
The patient is a woman who developed at 24 years of
age (2008) resting tremor at right arm, and afterwards
resting tremor and bradykinesia to the right-side of the
body. At 27 years of age, she came to the Parkinson In-
stitute, Milano, Italy, where clinical diagnosis of Parkin-
son’s Disease was established, confirmed by Dopamine
transporter SPECT imaging, which revealed reduction
mainly in the left striatum, while brain MRI was unre-
markable. She started dopaminergic therapy with excel-
lent motor response. She also presented cataract at right
eye at 17 years old, treated with surgery, and Premature
Ovarian Failure at 28 years of age. In the following 10
years, symptoms of PD increased gradually including
complex features of fatigue and myopathy without
pathological lesions at Electromyography (EMG).
Genetic analysis of the major PD genes disclosed the pres-
ence of a heterozygous genetic variant at exon 15 of the
POLG1 gene (NM_002693.2): c.2432A >G (p.Gln811Arg).
This missense variant is novel, and it has never been previ-
ously described in patients with POLG1 related syndromes,
and it is not present in GnomAD. The predictions based on
the sequence are largely in favor of a pathogenic effect
(DANN, DEOGEN2, EIGEN, FATHMM-MKL, M-CAP,
MVP, MutationAssessor, MutationTaster, PrimateAI,
REVEL and SIFT have a pathogenic prediction vs no benign
predictions; https://varsome.com).
The clinical picture (early onset cataract, POF, early
onset PD, fatigue and myopathy) and the presence of
probable pathogenetic mutation on the POLG1 gene
indicated a diagnosis of AUTOSOMAL DOMINANT
PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA
(OMIM: #157640).
Generation and characterization of iPSCs from a PD
patient carrying the variation p.Q811R in POLG1
To generate iPSCs, fibroblasts were collected from
the POLG1Q811R patient by punch skin biopsy,
grown, and reprogrammed by Sendai virus delivery
of the four Yamanaka factors OCT-3/4, KLF-4, SOX-
2 and c-MYC (Fig. 1a). After the expansion and bio-
banking of several reprogrammed clonal iPSC cell
lines, three clones, namely lines CSC-35E, CSC-35P
and CSC-35 V, were selected for further expansion
and characterization. For each line, quality control
was carried out according to previously described
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methods [31]. The three iPSC lines demonstrated al-
kaline phosphatase activity, loss of Sendai virus with
passaging, and expression of nuclear and cell surface
markers OCT4, NANOG and TRA-1–81, specific to
pluripotent stem cell stage (Fig. 1b, c). DNA sequen-
cing confirmed the presence of an A > G substitution
at position c.2432 resulting in the p.Q811R variation
(Fig. 1c). Cells had a normal karyotype and could
spontaneously differentiate into derivatives of the
three germ layers, confirmed by the presence of
endodermal marker alpha-fetoprotein, mesodermal
marker smooth muscle actin, and ectodermal marker
beta-III-tubulin (Fig. 1d, e). IPSC lines (CSC-37 N
and CSC-37R) derived from a non-demented healthy
individual of the same gender, were used as a con-
trol (Russ et al.; Pomeshchik et al.; manuscripts in
revision).
Generation and characterization of MDNS from
POLG1Q811R variant and healthy control iPSCs
To differentiate the iPSC lines into MDNS, we employed
dual inhibition of SMAD signaling through the addition of
SB-431542 and LDN-193189 to neuralize the cells, and
CHIR-99021 and sonic hedgehog to caudalize and ventra-
lize them, respectively (Fig. 2a [30];). Addition of FGF8 was
further used to instruct a midbrain floor plate identity [59].
It has been recently reported that iPSC-derived organoids
form dopaminergic neurons contained neuromelanin (NM)
granules if exposed to L-DOPA or dopamine (DA) [35].
Therefore, we supplemented the cultures with 50 μM of
DA at later stages of the differentiation, in combination
with neurotrophic factors. After a period of 100 days
in vitro (DIV), MDNS were collected for proteomic ana-
lysis, and cryo-sectioned and immune-stained (Fig. 2b).
MDNS predominantly contained MAP2-positive neurons
Fig. 1 Generation and characterization of iPSCs from a PD patient carrying the variation p.Q811R in POLG1. a Schematic representation of iPSC
generation and experimental workflow. b Bright field images showing iPSC colony formation, alkaline phosphatase activity, and loss of Sendai
virus in three iPSC clones derived from the POLG1 p.Q811R variant patient. Scale bars: 100 μm. c POLG1 p.Q811R variant iPSC clones stained for
the pluripotent markers NANOG, OCT4, TRA1–81. Scale bar: 100 μm. d DNA sequencing analysis confirming the presence of p.Q811R (c.2432 A >
G). e DNA fingerprinting confirming genetic equivalency to parental fibroblasts. f Immunocytochemistry for alpha-fetoprotein (AFP), beta-III-
tubulin (BIIITUB) and smooth muscle actin (SMA), confirming formation of all three germ layers. Scale bar: 100 μm
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expressing tyrosine hydroxylase (TH), the rate limiting en-
zyme in the production of DA (Fig. 2b), and few GFAP-
positive glia. To quantify the number of dopaminergic neu-
rons, MDNS were dissociated into single cell suspension,
and grown for 6 days on adherent surface (Fig. 2b, c, and
Additional file 2: Figure S1). Immunocytochemistry analysis
of the dissociated cultures revealed that both POLG1Q811R
and control cultures were composed of approximately
equal proportion of GFAP+ astrocytes and MAP2+ neu-
rons (Additional file 2: Figure S1). Around 30 to 40% of the
DAPI-positive cells expressed TH, out of which 80 to 100%
co-expressed the vesicular monoamine transporter 2
(VMAT2), necessary for DA transmission, as well as the
midbrain-related transcription factor FOXA2. Overall, there
was little variability in term of differentiation capability, be-
tween the different clones studied (Additional file 2: Figure
S1). Interestingly, there was a higher number of TH-
positive neurons in POLG1Q811R MDNS compare to con-
trol cultures. Additionally, we performed electrochemical
recordings for two of the lines studied, namely 37R (p24)
Fig. 2 Generation and characterization of MDNS from POLG1Q811R variant and healthy control iPSCs. a Schematic model illustrating the
differentiation strategy employed to obtain MDNS. Images illustrate cell morphology at each stage. b Immunostaining for brain cell subtype
markers GFAP and MAP2, midbrain marker FOXA2 and dopaminergic neuronal markers TH and VMAT, on cryosectioned MDNS aged 100 DIV and
dissociated cultures aged 106 DIV. Nuclei are counterstained with DAPI. Scale bars: 100 μm. c Quantification of MAP2+, GFAP+ and TH+ cells
relative to total number of DAPI-labeled cells, FOXA2+ and VMAT+ cells relative to TH-labeled cells in POLG1 variant and healthy control cultures.
Results are presented as ± SEM; n = 4 independent experiments; * indicates p < 0.05; unpaired t-test. d Electrochemical chronoamperometric
recordings showing DA release upon KCL stimulation by POLG1 variant and healthy control MDNS dissociated cultures
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and 35P (p16), to confirm the functionality of the dopamin-
ergic neurons present in culture, through release of DA
upon stimulation (Fig. 2d).
Western blot analysis reveals presence of oligomeric
species of α-synuclein of high molecular weight in
POLG1Q811R variant MDNS
Since PD pathogenesis is widely associated with α-
synuclein (aSYN) aggregation [69], we decided to first
assess the level of aSYN in the MDNS, prior to examin-
ing the changes in the proteome. Immunocytochem-
istry analysis of dissociated MDNS showed presence of
aSYN in TH-positive dopaminergic neurons for both
control and POLG1Q811R cultures (Fig. 3a and b). West-
ern blot analysis revealed no significant differences in
the levels of monomeric aSYN or phosphorylated aSYN
at position serine 129, between POLG1Q811R and con-
trol MDNS (Fig. 3c and d). However, immunoblot ana-
lysis for oligomeric aSYN (ASyO5) revealed the
presence of high molecular weight oligomers (approx.
190 kDa) in POLG1Q811R MDNS, compared to control
samples (Fig. 3c and d).
Analysis of the proteome of POLG1Q811R variant and
healthy control MDNS reveals alterations in several
pathways linked to PD pathogenesis
Mass-spectrometry based proteomic analysis allows for a ro-
bust characterization of disease-specific protein signatures
and identification of altered molecular pathways [11]. There-
fore, to gain insights into the cellular networks and pathways
that could potentially be altered in POLG1Q811R MDNS, we
performed liquid chromatography-tandem mass spectrom-
etry (LC-MS/MS). Quantitative proteomic profiling identi-
fied a total of 6749 proteins in POLG1Q811R and control
MDNS, 421 of which were mitochondrial (Additional file 1:
Table S1). Overall, POLGQ811R cultures showed differential
protein expression profile compared to control samples, as
confirmed by Principal Component Analysis (Fig. 4a). In
order to decrease the number of false positive hits, we only
considered protein change that had a P value < 0.001 as
significant.
Using this threshold cut-off, we found 61 proteins sig-
nificantly altered between POLG1Q811R and control
MDNS, with 24 down-regulated and 37 up-regulated
proteins in POLG1Q811R MDNS (Fig. 4b, c). The average
abundance of neuronal markers TH and TUBB3 was not
significantly altered between control and diseased
groups, and the levels of mitochondrial marker VDAC1
and the mitochondrial import receptor subunit TOM20
did not show any changes (Fig. 4d). Western blot ana-
lysis also confirmed no difference between the levels of
TH, VDAC1 and TOM20 (Fig. 4e, f), further confirming
that control and POLGQ811R MDNS had comparable
neuronal composition and number of mitochondria,
although there was a trend for increase in TH and a
slightly higher number of TH-positive dopaminergic
neurons in POLGQ811R MDNS.
To further understand the biological relevance of our
data, we performed Ingenuity Pathway Analysis (IPA) to
identify key regulated pathways corresponding to the pro-
tein changes identified in POLGQ8111R MDNS, and IPA
revealed several altered canonical pathways (Fig. 4g). Not-
ably, two of the up-regulated proteins in the in
POLG1Q811R MDNS, MARK11 and ARG2, appeared to be
linked to several pathways, including Parkinson’s signal-
ing, IL-10 signaling, AMPK-signaling, HIF-alpha signaling,
and pathways associated with urea cycle. MAPK11, also
known as p38b, belongs to a family of p38 mitogen acti-
vated protein kinases (MAPK) [6]. MAPK has been impli-
cated in induction of microglia activation, oxidative stress,
neuroinflammation and apoptosis in PD [33]. Cytoplasmic
arginase 1 and mitochondrial arginase 2 are responsible
for converting L-arginine to L-ornithine and urea, and in-
creased ARG2 expression has been observed in a patient
brain diagnosed with Alzheimer’s disease (AD) [27].
Disease and function analysis of the significantly al-
tered proteins also indicated that POLGQ811R was as-
sociated with alterations in pathways related to cell
death and survival, organismal injuries and abnormal-
ities, carbohydrate metabolism, cellular movements,
cellular development, cellular growth and cellular pro-
liferation (Fig. 4h).
Increased pigmentation of dopaminergic neurons in
POLG1Q811R variant MDNS may be linked to proteome
alterations
In accordance with previous observations [35], both control
and POLG1Q811R MDNS exhibited dark-pigmented de-
posits suggestive of accumulation of neuromelanin (NM) in
dopaminergic neurons (Fig. 5a). NM biosynthesis is in-
volved in regulating levels of cytosolic DA and DA qui-
nones [71]. The level of pigmentation was higher for
POLG1Q811R MDNS than control MDNS (Fig. 5a and b).
Cytosolic DA can oxidize to form aminochrome, a precur-
sor to NM that can form adducts with proteins involved in
pathogenesis of PD, including aSYN, and has been shown
to mediate mitochondrial and lysosomal dysfunction in PD
[14, 66]. Besides NM formation, DA oxidation can be pre-
vented by degradation of excess cytosolic DA by
monoamine oxidase (MAO) located on the outer mito-
chondrial membrane or by the uptake of DA into synaptic
vesicles by VMAT2 [49]. Additionally, to avoid neurotox-
icity, aminochrome may undergo two-electron reduction
by NQO1 to leukoaminochrome or conjugation with gluta-
thione to offer neuroprotection [64, 65]. Therefore, we
assessed levels of MAO-A, MAO-B, VMAT2, NQO1, and
glutathione S-transferase M2–2 responsible for conjugation
of aminochrome with glutathione. We also examined the
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level of glutathione peroxidase 4 GPX4, that has been found
to colocalize with NM and is significantly reduced in the
SNpc of PD patients, and which is increased when cell loss
occurs [8].
Quantitative proteomic analysis showed no signifi-
cant alterations in these proteins based on the P value
of 0.001 chosen for significance (Fig. 5c); however,
NQO1 showed trends towards upregulation in
POLG1Q811R MDNS. GPX4, known to colocalize with
neuromelanin showed a trend towards downregula-
tion, in line with the reduction observed in SNpc of
PD patients [8]. Interestingly, another glutathione S-
transferase isoform - GSTM3, was significantly upreg-
ulated in the POLG1Q811R MDNS, compare to control
(Fig. 5c). Although little is known about the role of
GSTM3 in aminochrome metabolism, upregulation of
GSTM3 in POLG1Q811R cultures may play a part in
protection against aminochrome-related oxidative
stress [5]. Proteome levels of MAO-A and MAO-B in
the POLGQ811R MDNS showed a trend towards a de-
crease. In line with that, Western blot analysis of
MAO-B levels revealed significant decrease in
POLG1Q811R MDNS compared to control samples
(Fig. 5d, e). Taken together, these data suggest that
Fig. 3 Western blot analysis reveals presence of oligomeric species of alpha-synuclein of high molecular weight in POLGQ811R variant MDNS. a
Immunostaining of pan-α-synuclein in POLG1 variant and healthy control MDNS dissociated cells 106 DIV. Scale bar: 100 μm. b Quantification of
aSYN-positive cells relative to total number of DAPI-labeled cells, in POLG1 variant and healthy control cultures. Results are presented as ± SEM;
n = 4 independent experiments; unpaired t-test. c Expression of monomeric alpha-synuclein, phosphorylated (pS129) alpha-synuclein, and
oligomeric (ASyO5) alpha-synuclein in POLG1 variant and healthy control MDNS. d Protein expression levels from (b) normalized to b-ACTIN.
Results are presented as ± SEM; n = 4 independent experiments. ** indicates p < 0.01; unpaired t-test
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increased pigmentation, suggestive of NM-
accumulation in the patient iPSC-derived brain dopa-
minergic neurons, could be due to decreased DA deg-
radation under the POLG1Q811R MDNS condition due
to the additive effect of lower levels of MAO-A and
MAO-B.
Western blot analysis reveals comparable levels of
mitochondria-associated proteins between healthy and
POLG1Q811R MDNS
In addition to POLG1, several other mitochondria-
associated proteins are known to be involved in the
maintenance of mitochondrial integrity and they may be
Fig. 4 Analysis of the proteome of POLG1Q811R variant and healthy control MDNS reveals alterations in several pathways linked to PD pathology.
a Protein expression variances between POLG1 variant and healthy control MDNS as principal component analysis (PCA). The first two axes (PCA
axis 1 and 2) of the PCA explain 51% of the variance. Red and turquoise dots represent healthy control and POLG1 variant clones/differentiations,
respectively. b Volcano plot displaying differentially expressed proteins in POLG1 variant and healthy control MDNS. Y-axis corresponds to the
log10 (p-value), and X-axis displays the log2 (fold change) values. The cut-off for significantly altered protein levels is set at P < 0.001. The red dots
represent significantly down-regulated proteins, and the green dots represent significantly up-regulated proteins. c Heat map representing color-
coded expression levels (red for down-regulated and green for up-regulated) of proteins differentially expressed between POLG1 variant (cyan)
and healthy control (orange) MDNS, with P < 0.001. d Abundance levels for neuronal markers TUBB3 and TH and mitochondrial markers TOMM20
and VDAC1 in POLG1 variant and healthy control MDNS identified by LC MS/MS quantitative proteomics. e and f Western blot confirming no
difference in the levels of TH, TOMM20 and VDAC1 between POLG1 variant and healthy control MDNS. Protein expression levels are normalized
to b-ACTIN. Results are presented as ± SEM, n = 4 independent experiments. g Ingenuity Pathways analysis (IPA) identifying regulated pathways
for differently expressed proteins POLG1 variant and healthy control MDNS. The figure shows the altered canonical pathways in IPA canonical
pathways analysis. The Y-axis shows the regulated pathways and the X-axis shows the –log(p-value). A cut-off of P = 0.001 was used for the
proteins to be included in the analyses. h Top diseases and functions identified based on the differentially expressed proteins, with indication of
scores and focus molecules for each category
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affected in PD [13]. Therefore, we assessed the levels of
several mitochondria-associated proteins involved in
mitochondrial function, including mitochondrial tran-
scription factor A (TFAM) essential for mitochondrial
DNA transcription [20, 42], as well as several mitochon-
drial proteins involved in regulation of mitochondrial
dynamics through fusion and fission [53, 62]. Proteomics
analysis (Fig. 6a) and Western blot analysis (Fig. 6b and
c) confirmed no significant changes for mitochondria
dynamics-associated proteins, between POLG1Q811R
MDNS and control samples.
Functional changes in glycolysis but not in the oxidative
phosphorylation of POLG1Q811R cultures support protein
alterations identified by quantitative proteomic analysis
IPA of significantly altered proteins revealed several
pathways associated with energy metabolism, includ-
ing 2-ketoglutarate dehydrogenase complex, pyruvate
fermentation to lactate, AMPK signaling and HIF1-
alpha signaling. Therefore, we decided to evaluate
rates of mitochondrial respiration and glycolysis in
POLG1Q811R and control cultures. First, we assessed
oxygen consumption rates (OCR) in POLG1Q811R and
control cultures using Seahorse XF Cell Mito Stress
Test Kit. There were no significant changes in basal
and ATP coupled and uncoupled respiration between
POLG1Q811R and control cultures (Fig. 7a); moreover,
the contributions of complex I and II of the respira-
tory chain towards maximum respiration were com-
parable. In line with that, proteomic analysis revealed
no changes in proteins associated with electron trans-
port chain complexes I-IV (Additional file 3: Figure
S2). Proteomic analysis identified two significantly up-
regulated enzymes in POLGQ811R MDNS, lactate de-
hydrogenase A (LDHA) and phosphofructokinase,
muscle type (PFKM), that are both involved in
Fig. 5 Increased neuromelanin production in POLGQ811R variant MDNS may be linked to proteome alterations. a and b Bright field images
showing the formation of NM-like pigmented granules in POLG1 variant and healthy control MDNS. Quantification of the pigmentation of the
MDNS in a.u. Results are presented as ± SEM; n = 80 MDNS counted; **** represents P < 0.0001; unpaired t-test. c Abundance levels for proteins
linked to neuromelanin production in POLG1 variant and healthy control MDNS identified by LC MS/MS quantitative proteomics. d and e Western
blot showing a significant decrease in levels of MAO-B in the POLG1 variant compared to healthy control MDNS. Quantification of MAO-B levels
are shown normalized to b-ACTIN. Results are presented as ± SEM; n = 4 independent experiments; ** indicates P < 0.01; unpaired t-test
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glycolysis (Fig. 7b) [81]. Western blot confirmed sig-
nificantly elevated levels of PFKM, a rate limiting en-
zyme of glycolysis, but did not show any significant
change in the levels of LDHA, although there was a
trend for increase (Fig. 7c). The discrepancy between
Western blot and proteomics data for LDHA levels
could be due to the low sensitivity of the Western
blot, as based on proteomic analysis, LDHA had a
very moderate increase (Fold change = 1.13 with P
value of 0.00006). We therefore decided to examine
the extracellular acidification rates (ECAR) from our
Mito Stress experiments. ECAR, indicative of lactic
acid production in glycolysis showed a significant in-
crease in basal glycolysis within POLG1Q811R cultures,
compared to control cultures (Fig. 7d). In a similar
manner, elevated aerobic glycolysis is observed in
many cancers [24], and many cancers are associated
with elevated expression of LDHA, responsible for
conversion of pyruvate to lactate at the last step of
glycolysis and regulated by HIF1-alpha signaling
amongst others [22]. LDHA was also upregulated in
POLG1Q811R cultures, and upregulation of LDHA
gene has been reported in PD patients [39].
Since our MDNS are not purely neuronal cultures, but
also contain a portion of astrocytes (Fig. 2b and c), which
are known to be highly glycolytic [7] we then performed
the same analysis on homogenous cultures of iPSC-
derived astrocytes from control and POLGQ811R lines. We
also assessed the OCR and ECAR in parental fibroblasts
to examine if the same phenotype could also be identified.
In contrast to our observations from MDNS, astrocytes
did not show any alterations in glycolysis, but exhibited
decreased rate of uncoupled respiration, and mitochon-
drial spare capacity (Fig. 8a). Fibroblasts from control and
POLGQ811R patient did not show any disease phenotype in
metabolic rates (Fig. 8b). Taken together, these results
suggest that the elevated glycolysis in POLGQ811R MDNS
may be attributed to the neurons.
Fig. 6 Western blot analysis reveals comparable levels of mitochondria-associated proteins between healthy and POLGQ811R variant MDNS. a
Abundance levels for mitochondrial markers MFN1, MFN2 and OPA1 involved in mitochondrial fusion, and MFF, FIS1 and MIEF1 regulating
mitochondrial fission in POLG1 variant and healthy control MDNS, identified by LC MS/MS quantitative proteomics. b Western blot analysis
confirms no difference in expression levels of mitochondrial transcription factor TFAM, fusion-related OPA1 and MFN2 and fission-related DRP1 in
POLG1 variant and healthy control MDNS. c Quantification of protein levels from (b), normalized to b-ACTIN. Results are presented as ± SEM; n = 4
independent experiments; unpaired t-test
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Discussion
Neurodegeneration of midbrain dopaminergic neu-
rons is a key hallmark of PD. Using reprogramming
technologies, it is possible to generate patient-
specific iPSCs, and further differentiate them into
brain cell types, opening up the possibility to assess
early cellular alterations associated with a patient
specific neuropathology. Here, we report a case study
of a female PD patient with a p.Q811R (c.2432A > G)
variation in the polymerase domain of the POLG1
gene. The patient presented cataract, early-onset par-
kinsonism, premature ovarian failure and sign of fa-
tigue and myopathy, resulting in the final diagnosis
of adPEO.
Fig. 7 Functional changes in glycolysis but not in the oxidative phosphorylation of POLG1 p.Q811R variant cultures support protein alteration
identified by quantitative proteomic analysis. a Oxygen consumption rates (OCRs) of 100 DIV dissociated POLG1 variant and healthy control
cultures, normalized to protein content, illustrating levels of basal respiration, ATP-coupled (oligomycin-sensitive) respiration, ATP-uncoupled
respiration after FCCP treatment, spare respiratory capacity, as well as contribution of mitochondrial complex I- and complex II-linked respiration
calculated from the effect of treatment with NV118, a cell-permeable prodrug of the complex II substrate succinate. Results are presented as ±
SEM, n = 4 independent experiments; unpaired t-test. b Abundance levels for LDHA and PFKM in POLG1 variant and healthy control MDNS
identified by LC MS/MS quantitative proteomics. c Western blot analysis shows significant upregulation of PFKM and a trend for increase of LDHA
in POLGQ811R MDNS compared to healthy control MDNS. Protein levels are normalized to b-ACTIN. Results are presented as ± SEM; n = 4
independent experiments; *** indicates P < 0.001; unpaired t-test. d Extracellular acidification rates (ECARs) of 100 DIV dissociated POLG1 variant
and healthy control cultures, normalized to protein content, illustrating levels of basal glycolysis and glycolytic reserve following treatment with
oligomycin. Results are presented as ± SEM n = 4 independent experiments. * indicates P < 0.05; unpaired t-test
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In order to investigate her parkinsonian phenotype on
a cellular level, we employed a recently developed proto-
col to obtain iPSCs-derived pigmented dopaminergic
neurons-containing MDNS. The MDNS were predomin-
antly composed of MAP2-positive neurons. They had a
midbrain dopaminergic identity, confirmed by co-
expression of VMAT2, FOXA2 and TH (Fig. 2b) [41].
Astrocytes (GFAP-positive), whose role in PD has re-
cently emerged [12], were also detected. Prior to the
read-outs, the MDNS were differentiated for 100 DIV.
Several recent studies showed that maintaining iPSC-
derived neural cultures beyond 100 days allows cells to
fully mature [67], and leads to the emergence of PD phe-
notypes including DA oxidation mediating mitochon-
drial and lysosomal dysfunction [14, 16, 46].
Quantitative proteomic analysis of MDNS yielded 61
differentially expressed proteins between POLG1Q811R
and control MDNS (Fig. 4b and c). Interestingly, the IPA
analysis identified several key pathways in POLG1Q811R
linked to increased neuroprotection and neuronal sur-
vival, which could explain the higher number of surviv-
ing dopaminergic neurons following dissociation of the
MDNS. The MAPK11 protein that was upregulated in
POLG1Q811R MDNS compared to control MDNS has
Fig. 8 Oxygen consumption and extracellular acidification rates of control and POLG1 p.Q811R variant fibroblasts and iPSC-derived astrocytes. a
Oxygen consumption rates (OCRs) and extracellular acidification rates (ECARs) of 100 DIV POLG1 variant and healthy control astrocytes, normalized
to protein content. OCR was used to calculate basal respiration, ATP-coupled and uncoupled respiration and spare respiratory capacity; glycolysis
and glycolytic reserve were calculated from ECAR. Results are presented as ± SEM, n = 3 independent experiments; * indicates P < 0.05; **
indicates P < 0.01; unpaired t-test. b Oxygen consumption rates (OCRs) and extracellular acidification rates (ECARs) of cultured fibroblasts from
healthy control and POLGQ811R patients, normalized to protein content. OCR was used to calculate basal respiration, ATP-coupled and uncoupled
respiration and spare respiratory capacity; glycolysis and glycolytic reserve were calculated from ECAR. Results are presented as ± SEM, n = 3
independent experiments; unpaired t-test
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been linked to several canonical pathways by IPA, in-
volving p38 MAPK signaling (Fig. 4g). P38 MAPK acti-
vation has been shown to contribute to PD pathology by
driving neuroinflammation and neurodegeneration
through activation of microglia and induction of NO
production [75]. Interestingly, extracellular NM activates
p38 MAPK pathway, also leading to microglial activation
[75]. Mitochondrial enzyme ARG2 was also upregulated
in POLG1Q811R MDNS, implicating urea cycle-related
pathways of arginine degradation, citrulline biosynthesis
and metabolism (Fig. 4g). A recent study identified in-
creased ARG2 in AD patient brain [27]. ARG2 is
thought to have a neuroprotective function due to its
negative effect on NO production [3]. However, NO,
known to lead to neurotoxicity when at high levels, is
also important for synaptic plasticity, and the observa-
tions of altered arginine metabolism in AD brain also
opens the question whether ARG2 increase is a conse-
quence or a cause in AD pathogenesis, and its implica-
tion in the progression of the disease [43]. The role of
the urea cycle and arginine metabolism in PD have not
been investigated yet, and could not be ruled out as po-
tential new mechanisms involved in PD pathogenesis.
Addition of DA during maturation stages of the
differentiation, triggered the darkening of the neu-
rons that composed the MDNS (Fig. 5a), suggesting
higher levels of NM in POLG1Q811R neurons [35].
NM is an insoluble pigment found in catecholamin-
ergic neurons of the SN and some other brain re-
gions, believed to protect neurons from neurotoxic
DA quinones and iron, but that may also increase
neuronal vulnerability during neurodegeneration [82].
However, the exact function and involvement of NM
in PD is still not fully understood. The proteomic
data together with the stronger pigmentation ob-
served was suggestive of higher NM production/ac-
cumulation or defect in NM degradation in the
POLG1Q811R MDNS compared to controls (Fig. 5a).
Indeed, proteomic analysis revealed a trend towards
decreased levels of DA degrading enzymes, MAO-A
and MAO-B, and a significant decrease of MAO-B
measured by Western blotting (Fig. 5d and e). How-
ever, PD pathology is normally associated with in-
creased MAO-B activity, and MAO-B inhibitors are
effective in the initial treatment of PD [38]. Our data
therefore raises the question whether PD dopamin-
ergic neurons are prone to accumulate NM very
early in the disease, compare to control dopamin-
ergic neurons. A possible explanation could be that
decrease in MAO-A and MAO-B levels was
prompted by the supplementation of the differenti-
ation media with DA. It has been reported that
chronic treatment with L-DOPA leads to inhibition
of MAO activity, an effect opposite of that of acute
L-DOPA treatment [57]. However, a similar inhibi-
tory effect would then be expected in the control
MDNS. It is also possible that the decrease in
MAO-B is a protective mechanism against mitochon-
drial pathology in POLG1Q811R MDNS, as the activ-
ity of the enzyme has been linked to increased ROS
and mitochondrial impairment [37, 70]. Notably, des-
pite PD therapies focusing predominantly on inhib-
ition of MAO-B to reduce DA breakdown and,
potentially, to decrease formation of toxic DA oxida-
tion products [77, 78], the MAO-B isoform is pre-
dominantly expressed in glial cells, while the DA
breakdown in neurons occurs mainly via the MAO-
A isoform [23]. A recent study assessed expression
levels of MAO-A and MAO-B in different brain re-
gions in patient with PD and PD-associated disor-
ders, postulating that elevated MAO-B could be a
marker of astrogliosis [73]. Reportedly, elevated
MAO-B was observed in the SNpc of patients with
progressive supranuclear palsy and, to some extent,
MSA, but no significant changes were detected in
PD patients, consistent with previous reports of lim-
ited astrogliosis in PD [72]. On the other hand, tran-
scriptional upregulation of MAO-A and MAO-B
have been reported in patients with PARK2 and
GBA variants in iPSC-derived neurons-based studies
[34, 76]. Employing a differentiation protocol that
includes addition of L-DOPA or DA may help in the
future to examine NM formation and DA metabol-
ism in PD neurons, in vitro.
Alteration in POLG1Q811R MDNS energy metabolism
was identified by the proteomic analysis and IPA (Fig. 4),
and confirmed by the increased glycolysis rate, but not the
oxidative phosphorylation in POLG1Q811R MDNS, com-
pared to controls (Fig. 7). Elevated glycolysis rate was in
line with the upregulation of PFKM essential for the drive
of glycolysis and LDHA that is responsible for the conver-
sion of pyruvate to lactate. Upregulation of genes encod-
ing LDHA, have been observed in animal models of PD
and samples from PD patients, and has been associated
with aging and increased mtDNA mutations, thought to
upregulate glycolysis as a compensatory mechanism for a
decrease in ATP production [39, 58, 60]. A study in mice
carrying mtDNA mutations expressing a proofreading-
deficient version of POLG1 reported elevated brain levels
of lactate due to an increase in LDHA/LDHB ratio [58].
Additionally, a recent study in a transgenic PS1/APP AD
mouse model revealed decreased content of lactate as well
as downregulation of LDHA and LDHB in PS1/APP mice,
but an increase in LDHA/LDHB ratio postulated to com-
pensate for neuronal lactate deficit and increase lactate
production [80]. It has also been shown that increase in
LDHA can mediate resistance to Aβ toxicity through up-
regulation of aerobic glycolysis as a protective mechanism,
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but it is possible that this effect is present in the pro-
dromal stages of AD [50], while at a later stages of the dis-
ease aerobic glycolysis and elevated lactate production
may contribute to the cognitive decline associated with
AD [28]. Notably, the elevated levels of LDHA in skeletal
muscle have also been reported in cohorts of patients with
PEO and mitochondrial encephalopathy lactic acidosis
and stroke-like episodes syndrome (MELAS) [61], suggest-
ing implications for not only PD, but also mitochondrial
diseases.
The implications of elevated glycolysis in PD is some-
what controversial. Mitochondrial dysfunction and in-
creased glycolysis has been observed in the peripheral
blood of prodromal and early-stage PD patients [68]. In
addition to that, PARK2 and PINK1, loss-of-function
variations of which lead to familial PD, have recently
been shown to negatively regulate the Warburg effect, a
switch from mitochondrial respiration to aerobic gly-
colysis when oxygen supply is normal in cancer [2, 79].
These results implicate increased glycolysis in the patho-
genesis of PD. At the same time, two recent studies
showed neuroprotective effect of glycolysis-enhancing
drugs Meclizine and Terazosin, suggesting that glycolysis
can provide beneficial effect when energy metabolism
and ATP production is compromised [15, 32].
Our iPSCs-based model, for investigating neuronal
phenotype and pathology in POLGQ811R variant with
early-onset PD, is a valuable tool to gain insights into
cellular mechanisms affected in this patient (catechol-
amine degradation, aSYN aggregation, energy metabol-
ism) and to establish a link between clinical and cellular
phenotypes.
Materials and methods
Generation and maintenance of iPSCs
Human dermal fibroblasts were obtained by punch skin
biopsy from a PD patient carrying heterozygous p.Q811R
variation in the POLG1 gene (POLG1Q811R/WT; referred
to as POLG1Q811R in the text and figures), after written in-
formed consent. Fibroblasts were cultured and expanded
in culture medium containing DMEM media (Thermo
Fisher Scientific), 10% fetal bovine serum and 1%
Penicillin-Streptomycin. For reprogramming, fibroblasts
were transduced using CytoTune™-iPS 2.0 Sendai repro-
gramming kit (Thermo Fisher Scientific) according to
manufacturer’s instructions. The cells were maintained in
fibroblast media with daily media changes until day 6,
when the cells were re-seeded onto a layer of irradiated
mouse embryonic fibroblasts (MEF) feeder cells in WiCell
medium composed of advanced DMEM/F12, 10% Knock-
Out Serum Replacement, 2 mML-glutamine, 1% non-
essential amino acids (all from Thermo Fisher Scientific),
50 μM β-mercaptoethanol (Sigma-Aldrich) and 20 ng/ml
FGF2 (Thermo Fisher Scientific). Three to four weeks
later, individual colonies were picked and expanded, be-
fore being bio-banked and characterized, similarly to our
previous lines [31].
Differentiation of iPSCs towards midbrain dopaminergic
identity
To differentiate the iPSC into midbrain dopaminergic
neurons, we modified previously established protocols
[35] was used. Briefly, following expansion, iPSCs were
detached with dispase II (Thermo Fisher Scientific) and
seeded in ultra-low attachment flasks in WiCell media
supplemented with 10mM ROCK inhibitor Y27632
(Sellekchem) and 20 ng/ml FGF2 (Thermo Fisher Scien-
tific). The following day (denoted as day 0), the media
was changed to neural induction medium (NIM) com-
posed of advanced DMEM/F12, 2 mML-glutamine, 1%
non-essential amino acids, 1% N2 supplement, 1%
Penicillin-Streptomycin (all Thermo Fisher Scientific).
Media was supplemented with 0.1 μM LDN (Stemgent),
10 μM SB 431542 (Sigma-Aldrich), 200 ng/ml SHH-C
(Thermo Fisher Scientific), 1 μM SAG (Sellekchem) and
0.8 μM CHIR (Sigma-Aldrich) (day 0–4) and replaced
every other day. On day 6 SB and SHH-C were removed
from the media and SAG was increased to 2 μM, and on
day 10 LDN was removed also. From day 12 onwards
the cells were grown in NIM supplemented with 100 ng/
ml FGF8 (Thermo Fisher Scientific) and 2 μM SAG, 10
ng/ml BDNF (R&D Systems) and 200 μM AA (Sigma-
Aldrich). From day 22, the media was replaced with
neural differentiation medium (NDM) containing Neu-
robasal media with 2 mML-glutamine, 1% non-essential
amino acids, 1% N2 supplement, 1% B27 without vita-
min A, 1% Penicillin-Streptomycin (all from Thermo
Fisher Scientific), supplemented with 100 ng/ml FGF8
and 2 μM SAG, 10 ng/ml BDNF, 10 ng/ml GDNF (R&D
Systems), 200 μM AA, 500 μM db-cAMP (Sigma-Al-
drich) and 1 ng/ml TGFb (Peprotech). From day 30 on-
wards, FGF8 and SAG were removed from the media
and 50 μM DA (Sigma-Aldrich) was added to the media
to promote formation of neuromelanin. For the read-
outs, differentiated spheroids at 100 DIV were either col-
lected, washed and snap-frozen or fixed, for analysis of
the proteome, and immunocytochemistry (ICC), respect-
ively, or dissociated using 0.05% Trypsin-EDTA
(Thermo Fisher Scientific) and re-seeded on plates
coated with 40 μg/ml poly-ornithine (Sigma-Aldrich)
and 15 μg/ml laminin (Thermo Fisher Scientific), ICC,
amperometry and SeaHorse analysis.
Differentiation of iPSCs towards astrocytes
The differentiation of healthy and POLGQ811R iPSCs into
astrocytes followed the same protocol as for midbrain
dopaminergic identity, for the first 10 days. From day 12,
cells were differentiated in NIM media supplemented
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with 100 ng/ml FGF8 and 2 μM SAG until day 30. Then,
cells were dissociated, filter-strained (100 μm), and
transferred to new ultra-low-adherent flasks with neural
expansion medium (NEM) containing DMEM-F12, 2
mML-glutamine, 1% non-essential amino acids, 1% N2
supplement, 1% B27 without vitamin A, 1% Penicillin-
Streptomycin, and 0.2 μg/ml heparin (Sigma-Aldrich),
supplemented with 20 ng/ml FGF2 and 20 ng/ml EGF
(Peprotech). On day 60, spheroids were washed and dis-
sociated into single cells, and seeded to adherent culture
flasks coated with Poly-L-ornithine/laminin, in NEM
containing 20 ng/ml CNTF (R&D Systems). Finally, from
day 80 onwards, astrocytes were cultured in NDM with
20 ng/ml CNTF. Cells were passaged at confluency.
Amperometry
In vitro high-speed chronoamperometric measurements
(2 HZ) of DA release, were performed according to pre-
viously described protocol [4, 29], on dissociated spher-
oids seeded onto 4 well-plates at a density of about 80,
000 cells/cm2. Briefly, Recording was done using FAST-
16 mk III hardware (Quanteon) coupled to Nafion®-
coated carbon fiber electrodes (30 μm diameter, 150 μm
length). A square wave potential of 0.55 V; 0.0 V resting
potential was applied vs an Ag/AgCl reference. Prior to
recording the electrode was calibrated at room
temperature in stirred 0.1M PBS by on addition of As-
corbic Acid (20 mM) followed by three additions of DA
(2 μM). The electrodes used displayed a linearity correl-
ation of > 0.99, a selectivity of DA over ascorbic acid of
> 1000:1, and a limit of detection below 0.01 μM.
Immunocytochemisty
For ICC differentiated spheroids were either collected or
dissociated at 100 DIV and seeded onto poly-ornithine/
laminin-coated clear bottom 96-well microplates (Grei-
ner Bio One) at 200,000 cells/cm2 and fixed in 4% para-
formaldehyde (Sigma-Aldrich). After fixation cells were
washed in PBS, and fixed spheroids were equilibrated in
30% sucrose overnight. Fixed spheroids were then
mounted in OCT (Sigma-Aldrich) and cut using a cryo-
stat into 20 μM sections. Dissociated cells and spheroid
sections were blocked in 10% donkey serum in PBS with
0.1% (dissociated cells) PBS-Tween 20 with or 0.3% (sec-
tions) Triton-X (Sigma-Aldrich). Primary antibodies
were diluted in blocking solution and incubated over-
night at 4 °C: mouse anti-AFP (Sigma-Aldrich, A8452, 1:
500), mouse anti-SMA (Sigma-Aldrich, A2547, 1:500),
rabbit anti-TUJ1 (Covance, PRB-435P, 1:500), mouse
anti-Oct4 (Millipore, MAB4401, 1:200), mouse anti-
Nanog (BD Biosciences, 560,483, 1:200), mouse anti-
TRA-1-81 (Thermo Fisher Scientific, 411,100, 1:200),
rabbit anti-TH (Millipore, AB152, 1:500), mouse anti-
TH (Millipore, MAB318, 1:250), sheep anti-TH (Abcam,
ab113, 1:500), goat anti-FOXA2(Santa-Cruz, sc11415, 1:
250), rabbit anti-VMAT2 (Immunostar, 20,042, 1:500),
mouse anti-aSYN (Santa-Cruz, sc12767, 1:200), rabbit
anti-GFAP (DAKO, Z0334, 1:2000), chicken anti-MAP2
(Abcam, ab92434, 1:2000). AlexaFluor-488, AlexaFluor-
555 and AlexaFluor-647-labelled secondary antibodies
(Thermo Fisher Scientific) were used at 1:400 in PBS or
PBS-Tween 20 at RT for 1 h. DAPI (1:10,000) was used
for nuclei counterstaining. Images were acquired using
an inverted epifluorescence microscope LRI-Olympus
IX-73, Metamorph and ImageJ software were used for
image analysis and quantification.
Western blot
Protein extraction was performed using M-PER (Thermo
Fisher Scientific) following manufacturer’s instructions.
Pierce BCA Protein Assay Kit (Thermo Fisher Scientific)
was used to quantify the protein. 13 μg of protein from
each sample was loaded on Bolt 4–12% Bis-Tris Plus
Gels (Thermo Fisher Scientific) and then transferred to
nitrocellulose membranes using iBlot transfer device
(Thermo Fisher Scientific). Membranes were blocked in
with either 5% skim milk (Sigma-Aldrich) or 5% BSA
(for phosphorylated protein) (VWR) diluted in PBS-
Tween 20. The membranes were incubated with primary
antibodies diluted in blocking solution at 4 °C, overnight:
mouse anti-Actin (Sigma-Aldrich, A5441, 1:20000),
rabbit anti-ASYN (Cell Signaling, 2642S, 1:1000), mouse
anti-ASyO5 (Agriseria, AS132718, 1:1000), rabbit anti-
phosphoS129 (Abcam, ab168381, 1:500), mouse anti-
DRP1 (Abcam, ab56788, 1:500), rabbit anti-MAO-B
(Abcam, ab175136, 1:2000), mouse anti-MFN2 (Abcam,
ab56889, 1:500), anti-rabbit anti-OPA1 (Abcam,
ab157457, 1:500), rabbit anti-TH (Millipore, AB152, 1:
2000), mouse anti-TH (Millipore, MAB318, 1:1000),
mouse anti-TOMM20 (Abcam, ab56783), rabbit anti-
TOMM20 (Santa Cruz, sc11415, 1:200), rabbit anti-
TFAM (Abcam, ab131607, 1.200), rabbit anti-VDAC1
(Abcam, ab15895, 1:1000), rabbit anti-LDHA (Cell Sig-
naling, #2012, 1:1000), rabbit anti-PFKM (Abcam,
ab97353, 1:1000). Washed membranes were incubated
with peroxidase-conjugated secondary antibody (R&D
Systems) at 1:2000 and developed using ChemiDoc gel
imaging system (Bio-Rad). Analysis of the blots was per-
formed using Bio-Rad Image Lab software and the pro-
tein levels were normalized to beta actin.
Oxygen consumption rate
Control and POLGQ811R MDNS dissociated cultures, as-
trocytes and fibroblasts were seeded onto poly-
ornithine/laminin-coated Seahorse 96-well plates (Agi-
lent Technologies) at 200,000 to 300,000 cells/cm2.
Empty wells were used as background controls. Oxygen
consumption rates (OCR) and extracellular acidification
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rate (ECAR) analysis was performed 2 days later, on the
Seahorse XFe 96 analyzer using the Seahorse XF Mito
Stress Test Kit (Agilent Technologies), according to
manufacturer’s instructions. Briefly, cells were washed
three times and incubated in XF-Base medium supple-
mented with 5 mM pyruvate, 2 mM L-Glutamine and 10
mM glucose in non-ventilated, non-CO2 incubator at
37 °C for 1 h. For measurements, three cycles for MDNS
dissociated cultures and 5 cycles for astrocytes and fibro-
blasts of 30 s mix, followed by 2 min measurement were
used for the baseline and sequential treatments of 1 μg/
mL Oligomycin, 1 μM FCCP, 2uM Rotenone (for
MDNS, rotenone was combined with 500 μM succinate
prodrug NV118), 1 μg/mL Antimycin. Background-
corrected measurements of OCR and ECAR were nor-
malized to the total protein level using Protein Assay Kit
II (Bio-Rad).
LC MS/MS proteomics
Protein extraction for proteomic analysis
Cell pellets were homogenized using a FastPrep®-24 in-
strument (MP Biomedicals, www.mpbio.com) with Lys-
ing Matrix D for five repeated cycles (speed 6.5 m/s, 40
s/cycle) in 200 μl of the buffer containing 2% sodium do-
decyl sulfate and 50 mM triethylammonium bicarbonate
(TEAB). Samples were centrifuged at 16000 g for 10 min
and the supernatants were transferred to clean tubes.
The lysis tubes were washed with 100 μl of the lysis buf-
fer, centrifuged at 16000 g for 10 min, the supernatants
were combined with the corresponding lysates from the
previous step. Protein concentration in the combined ly-
sates was determined using Pierce™ BCA Protein Assay
Kit (Thermo Scientific) and the Benchmark™ Plus micro-
plate reader (BIO-RAD) with bovine serum albumin
(BSA) solutions as standards. A representative reference
sample was prepared, containing equal amounts from
the 8 individual samples.
Tryptic digestion and tandem mass tag (TMT) labelling
Aliquots containing 30 μg of each sample including
the reference were reduced with 100 mM DL-
dithiothreitol (DTT) at 56 °C for 30 min. The re-
duced samples were processed using the modified
filter-aided sample preparation (FASP) method (Wis-
niewski JR et al. Nat Methods. 2009 May;6(5):359–
62). In short, reduced samples were transferred to
30 kDa MWCO Pall Nanosep centrifugation filters
(Sigma-Aldrich) and washed twice with 8 M urea.
Additional washes with digestion buffer (1% sodium
deoxycholate in 50 mM TEAB) was performed before
and after alkylation with 10 mM methyl metha-
nethiosulfonate for 30 min at room temperature. Pro-
tein digestions were performed using Trypsin (Pierce
MS grade) in digestion buffer, first with 0.3 μg
Trypsin at 37 °C overnight followed by new addition
of 0.3 μg trypsin and incubation t at 37 °C for 2 h.
Produced tryptic peptides were collected by centrifu-
gation and labelled using TMT 10-plex isobaric mass
tagging reagents (Thermo Scientific) according to the
manufacturer instructions. Labelled samples were
combined and sodium deoxycholate was removed by
acidification with 10% TFA.
The combined TMT-labeled sample was fraction-
ated into 40 primary fractions by basic reversed-phase
chromatography (bRP-LC) using a Dionex Ultimate
3000 UPLC system (Thermo Fischer Scientific). Pep-
tide separations were performed using a reversed-
phase XBridge BEH C18 column (3.5 μm, 3.0 × 150
mm, Waters Corporation) and a linear gradient from
3 to 40% solvent B over 17 min followed by an in-
crease to 100% B over 5 min. Solvent A was 10 mM
ammonium formate buffer at pH 10.00 and solvent B
was 90% acetonitrile, 10% 10 mM ammonium formate
at pH 10.00. The primary fractions were concatenated
into 20 fractions (1 + 21, 2 + 22, … 20 + 40), evapo-
rated and reconstituted in 15 μl of 3% acetonitrile,
0.2% formic acid for nLC-MS/MS analysis.
nLC-MS/MS
The fractions were analyzed on an orbitrap Fusion™
Lumos™ Tribrid™ mass spectrometer interfaced with
Easy-nLC1200 liquid chromatography system (Thermo
Fisher Scientific). Peptides were trapped on an Ac-
claim Pepmap 100 C18 trap column (100 μm× 2 cm,
particle size 5 μm, Thermo Fischer Scientific) and
separated on an in-house packed analytical column
(75 μm× 30 cm, particle size 3 μm, Reprosil-Pur C18,
Dr. Maisch) using a linear gradient from 5 to 33% B
over 77 min followed by an increase to 100% B for 3
min, and 100% B for 10 min at a flow of 300 nL/min.
Solvent A was 0.2% formic acid and solvent B was
80% acetonitrile, 0.2% formic acid. MS scans were
performed at 120000 resolution, m/z range 375–1375.
MS/MS analysis was performed in a data-dependent,
with top speed cycle of 3 s for the most intense
doubly or multiply charged precursor ions. Precursor
ions were isolated in the quadrupole with a 0.7 m/z
isolation window, with dynamic exclusion set to 10
ppm and duration of 45 s. Isolated precursor ions
were subjected to collision induced dissociation (CID)
at 35 collision energy with a maximum injection time
of 50 ms. Produced MS2 fragment ions were detected
in the ion trap followed by multinotch (simultaneous)
isolation of the top 10 most abundant fragment ions
for further fragmentation (MS3) by higher-energy col-
lision dissociation (HCD) at 65% and detection in the
Orbitrap at 50000 resolutions, m/z range 100–500.
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Proteomic data analysis
Identification and relative quantification were performed
using Proteome Discoverer version 2.2 (Thermo Fisher
Scientific). The database search was performed using the
Mascot search engine v. 2.5.1 (Matrix Science, London,
UK) with MS peptide tolerance of 5 ppm and fragment
ion tolerance of 0.6 Da. Tryptic peptides were accepted
with 1 missed cleavage; methionine oxidation was set as
a variable modification, cysteine methylthiolation, TMT-
6 on lysine and peptide N-termini were set as fixed
modifications. Percolator was used for PSM validation
with the strict FDR threshold of 1%.
Quantification was performed in Proteome Discoverer
2.2. TMT reporter ions were identified in the MS3 HCD
spectra with 3 mmu mass tolerance, and the TMT re-
porter intensity values for each sample were normalized
within Proteome Discoverer 2.2 on the total peptide
amount. Only the unique identified peptides were con-
sidered for the relative quantification.
Differential expression analysis
Differentially expressed proteins were identified by using
unpaired t-test analysis with a P-value cut-off of 0.001.
The differentially expressed proteins identified from
unpaired t-tests were visualized using a volcano plot,
that displays log2-fold-change against -log(10) (p-value)
from the t-test.
To graphically present the distribution of the differen-
tially expressed proteins identified for the samples a
heatmap plot was used after non-supervised hierarchical
clustering, with a P-value cut-off of 0.001 log2 trans-
formed data, using the R-package gplots.
Protein expression variances between groups are dis-
played as principal component analysis (PCA) to show
similarities or differences among the samples belonging
to the two different groups using the R-packages prcomp
and ggplot2 on log2 transformed data.
Statistical analyses were performed using the R soft-
ware (version 3.6.0, https://www.r-project.org/, The R
project, Vienna, Austria).
Ingenuity pathway analysis
To identify significant canonical pathways in which differen-
tially expressed proteins were enriched, pathway enrichment
analysis was conducted with the web-based pathway analysis
tool IPA (Ingenuity, Systems, www.ingenuity.com, Redwood
City, CA). Differentially expressed proteins were uploaded
into IPA along with the protein identifiers, p-values and fold
change values. A cut-off of a 0.001 P-value was used for the
proteins to be included in the analyses. Each identifier was
mapped to the Ingenuity knowledge base. Canonical path-
way analysis identified the pathways, from the IPA library of
canonical pathways, which were most significant to the in-
put data set firstly using a ratio of the number of proteins
from the dataset in a given pathway divided by the total
number of molecules that make up the canonical pathway
and secondly a Fisher’s exact test to assess the probability of
the association to the canonical pathway.
Statistics
Statistical analysis was performed using Prism 7 software
(GraphPad). Data are presented as mean ± standard error
of the mean. Comparisons between control and diseased
groups (N = 4 per group) were analyzed using an unpaired
t-test. A value of p < 0.05 was considered to be statistically
significant for all measurements, except for the proteomic
analysis where p < 0.001 was considered to be statistically
significant. To calculate the intensity of pigmentation of
the MDNS, we measured the pixels value ranging from 0
(black) to 255 (white) on a grey scale, and presented the
results as pixel values subtracted from the white value
(255); up to 80 MDNS counted per group.
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Additional file 1: Table S1. TMT-LC-MS raw data.
Additional file 2: Figure S1. Characterization of the differentiated
MDNS. (A) Quantification of MAP2+, GFAP+ and TH+ cells relative to total
number of DAPI-labeled cells, shown per differentiation. (B) FOXA2+,
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